Summary of findings tables for measurement property reviews: The evolution and application of OMERACT's summary of measurement properties (SOMP) Table.

Background: Literature reviews of measurement properties of an outcome measurement instrument are fast becoming the evidence base for making decisions about the suitability of the instrument for a given application. In our case at OMERACT it is the fitness of an instrument for inclusion in a Core Outcome Set. Transparency in the processes and decision making at each step are important to allow consumers of the literature review to have a clear understanding of the decision-making process.

The NIH BRAIN Initiative's Impacts in Systems and Computational Neuroscience, 2014-2023.

At the 10-year anniversary of the NIH BRAIN Initiative, this report analyzes the impact of the initiative's functional neuroscience ecosystem as funding experiments in the domains of systems and integrative neuroscience, and computational neuroscience, with an eye on comparison with other funding models and best practices.

Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 Study.

Objective: To determine whether higher serum exposure during subcutaneous (SC) abatacept (ABA) treatment was associated with an increased infection risk in adult patients with early rheumatoid arthritis (RA).

Methods: Data from Assessing Very Early Rheumatoid Arthritis Treatment-2 (AVERT2; ClinicalTrials.gov: NCT02504268), a randomized, placebo-controlled study in anticitrullinated protein antibody-positive patients with early RA, were analyzed.

Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry.

Objectives: To compare effectiveness of tofacitinib versus tumor necrosis factor inhibitors (TNFi), and across tofacitinib lines of therapy, in patients with rheumatoid arthritis (RA), using US CorEvitas RA Registry data.

Methods: Analysis included patients with RA initiating tofacitinib or TNFi with a 12-month follow-up visit between November 2012-February 2021. Primary (Clinical Disease Activity Index-defined low disease activity [CDAI-LDA: CDAI ≤ 10]) and secondary (clinical/disease activity/patient-reported) effectiveness outcomes were assessed at month 12.

Correlation Between Pain, Disease Activity, and Rheumatoid Factor Positivity in Patients with Chikungunya Arthritis.

Chikungunya fever (CHIKF) is an acute viral disease caused by the chikungunya virus (CHIKV) transmitted by mosquitoes. The acute phase presents with limited symptoms and low mortality, but approximately half of cases progress to more chronic illness with persistent and disabling joint symptoms. To better characterize the burden of chronic disease, we analyzed the relationship between pain intensity, the Disease Activity Index by DAS28-ESR, rheumatoid factor (RF) positivity, sex, and age in a retrospective cohort of 133 patients with chikungunya arthritis (CHIKA).